8th Biennial Symposium of the International Eosinophil Society, Inc.

描述(由申请人提供)：R13为第八届双年一度的嗜酸性粒细胞研讨会--“2013年嗜酸粒细胞研讨会”--提供会议支持，该研讨会将于2013年7月13日至17日在英国牛津大学凯布尔学院举行，由国际嗜酸性粒细胞协会(IES)赞助(www.eosinophil-Social ety.org)。会议邀请了约30名特邀演讲者和约150名与会者。当地组委会与IES科学计划委员会协商，准备了一项基础、翻译和临床研究的尖端计划。课程内容包括：(1)嗜酸性粒细胞发育、功能成熟和死亡的调控；(2)作为免疫调节细胞的嗜酸性粒细胞；(3)嗜酸性粒细胞的功能--运输、激活和信号传递；(4)嗜酸性粒细胞和胃肠道。 疾病(5)嗜酸性粒细胞和宿主防御(5)嗜酸性粒细胞疾病的实验模型6)嗜酸性疾病的新治疗方法7)高嗜酸性粒细胞综合征8)针对研究嗜酸性粒细胞技术领域的新手的新的实用讲习班。这次会议的中心目标是提供一个高度互动的跨学科论坛，供变态反应、免疫学、血液学和癌症领域的初级和高级科学家就嗜酸性粒细胞在健康和疾病中的作用进行科学交流和合作。一个主要的目标是将在嗜酸性粒细胞生物学方面有专长的非临床科学家和对嗜酸性粒细胞相关疾病感兴趣的临床科学家聚集在一起，以改进 了解疾病机制和嗜酸性粒细胞功能的意义。第二个目标是促进年轻调查人员的发展和兴趣，以帮助支持他们的 并提供新一代的嗜酸性粒细胞。为了实现这一点，会议将有一个类似Keystone的结构，所有代表在一个地点共同用餐和住宿，以鼓励非正式互动。将通过科学和社会方案强调创建一个全球嗜酸性粒细胞科学家社区。这次会议将特别及时，因为将提交新一代生物疗法的临床试验数据，这种疗法专门阻断嗜酸性粒细胞介导的炎症通路，为嗜酸性粒细胞在疾病中的作用提供明确的数据。该研讨会非常强调跨学科，涵盖了一些重要的全球性疾病，如哮喘、嗜酸性食管炎、寄生虫病和高嗜酸性粒细胞综合征。研讨会包括全体会议和海报会议。全体会议将结合该领域领导者的最新演讲，以及关于最近高影响力数据的尖端演讲。每节课将有两次口头陈述，取自提交的摘要。三次海报会议将无人反对，并给予高度优先考虑。我们有两个获奖讲座，第五届Ehrlich奖授予在该领域做出重大总体贡献的科学家，Gleich奖授予前两年发表的论文影响最大的科学家。

DESCRIPTION (provided by applicant): R13 conference support is requested for the 8th Biennial Eosinophil Symposium - "Eosinophils 2013", to be held from 13-17 July 2013 at Keble College, Oxford University, Oxford, UK, under the auspices of the International Eosinophil Society, Inc. (IES) (www.eosinophil-society.org). The meeting hosts ~30 invited speakers and ~150 participants. A cutting edge program of basic, translational, and clinical research has been prepared by the Local Organizing Committee in consultation with the Scientific Program Committee of IES. The programme will include sessions on (1) regulation of eosinophil development, functional maturation and death, (2) eosinophils as immunoregulatory cells, 3) eosinophil functions - trafficking, activation, and signaling, (4) eosinophils and gastrointestinal disease (5) eosinophils and host defence (5) experimental models of eosinophilic disease 6) new treatments for eosinophilic disease 7) hypereosinophilic syndrome 8) a new practical workshop aimed at new comers to the field on techniques for studying eosinophils. The central goal of this conference is to provide a highly interactive, interdisciplinary forum for scientific exchange and collaboration amongst junior and senior scientists in the fields of allergy, immunology, hematology, and cancer in relation to the role of the eosinophil in health and disease. A primary objective is to bring together non- clinical scientists with expertise in eosinophil biology, and clinical scientists interested in eosinophil associated disease, to improve understanding of disease mechanisms and the significance of eosinophil functions. A second objective is to foster the development and interests of younger investigators to help support their careers and provide a new generation of eosinophils. To accomplish this, the meeting will have a Keystone- like-structure with all the delegates in a single venue sharing meals and accommodation on the same footing to encourage informal interactions. There will be an emphasis through both the scientific and social programmes on creating a global community of eosinophil scientists. This meeting will be particularly timely because data from clinical trials o a new generation of biological therapies, which specifically block eosinophil-mediated inflammatory pathways, will be presented providing definitive data on the role of eosinophils in disease. The symposium, with its strong emphasis on inter-disciplinarity, covers important global diseases such as asthma, eosinophilic oesophagitis, parasitic disease and hypereosinophilic syndrome. The symposium consists of plenary and poster sessions. The plenary sessions will combine state of the art talks from leaders in the field together with cuttin edge lectures on recent high impact data. Each session will have two oral presentations taken from submitted abstracts. Three poster sessions will be unopposed and given high priority. We have two prize lectures, the 5th Ehrlich award for the scientist who has made a major overall contribution to the field, and the Gleich award for the scientist with the highest impact paper published over the previous two years.